US · JAGX
Jaguar Health, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- San Francisco, CA 94104
- Website
- jaguar.health
Price · as of 2024-12-31
$6.69
Market cap 1.93M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $69.47 | +938.42% |
| Intrinsic Value(DCF) | $5.77 | -13.75% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | $513,843,744.00 | ||||
| 2016 | $400,443,744.00 | $1,407,794,499,724.80 | $0.00 | $0.00 | $3,098,140,982,282,708.50 |
| 2017 | $79,025,624.00 | $132,243,175,239,459.19 | $0.00 | $0.00 | $0.00 |
| 2018 | $3,425,625.00 | $325,936,972,323.60 | $0.00 | $0.00 | $0.00 |
| 2019 | $197,775.00 | $122,314,892.40 | $0.00 | $0.00 | $0.00 |
| 2020 | $732,375.00 | $385,850,377.20 | $0.06 | $0.00 | $0.00 |
| 2021 | $43,875.00 | $3,917,868.30 | $0.00 | $0.00 | $429,453,056.04 |
| 2022 | $1,740.00 | $696.00 | $297,428.02 | $0.00 | $0.00 |
| 2023 | $123.00 | $49.20 | $0.00 | $0.00 | $25,361.07 |
| 2024 | $14.43 | $69.47 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Jaguar Health, Inc.'s (JAGX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $69.47
- Current price
- $6.69
- AI upside
- +938.42%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$5.77
-13.75% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| JAGX | Jaguar Health, Inc. | $6.69 | 1.93M | +938% | -14% | — | — | -0.11 | 0.58 | 0.36 | -0.89 | — | -0.38 | 83.27% | -263.76% | -329.30% | -637.50% | -86.37% | -74.93% | 5.01 | -133.47 | 1.63 | 0.49 | -0.78 | -9513.00% | 1975.00% | -1091.00% | -697.04% | -1.49 | -82.96% | 0.00% | 0.00% | 49.45% | -1.06 | -1.11 | 2.80 | -10.43 |
| BDRX | Biodexa Pharmaceuticals P… | $1.08 | 90.59K | +65,720% | — | — | — | -0.25 | 0.17 | — | -0.05 | -0.06 | 0.53 | 0.00% | — | — | -88.14% | -269.10% | -45.25% | 0.09 | — | 1.75 | 0.47 | 0.10 | 40524.00% | -10000.00% | 8388.00% | -924.24% | -2.44 | -397.95% | 0.00% | 0.00% | 0.00% | -0.05 | -0.04 | — | -15.86 |
| CNSP | CNS Pharmaceuticals, Inc. | $3.11 | 1.79M | — | — | — | — | -0.68 | 1.63 | — | -0.27 | — | 1.63 | 0.00% | — | — | -1703.39% | 642.50% | -285.68% | 0.05 | -924.50 | 3.43 | 2.91 | 0.41 | -3522.00% | — | 2102.00% | -169.67% | -6.78 | 738.03% | 0.00% | 0.00% | 58.36% | -0.27 | -0.23 | — | -15.99 |
| GNPX | Genprex, Inc. | $2.00 | 3.26M | — | — | — | — | -0.06 | 0.84 | — | 0.01 | — | 0.84 | 0.00% | — | — | -467.24% | -6073.62% | -285.38% | 0.00 | — | 0.83 | 0.64 | 0.08 | -7633.00% | — | -3088.00% | -1259.09% | -6.85 | -4919.06% | 20346.13% | -1312.70% | 20346.13% | 0.01 | 0.01 | — | -69.29 |
| GRI | GRI Bio, Inc. | $2.55 | 229.07K | +6,695% | — | — | — | -0.02 | 0.04 | — | 0.66 | — | 0.04 | 0.00% | — | — | -238.17% | 791.34% | -166.00% | 0.01 | — | 3.25 | 3.11 | 0.68 | -9212.00% | -10000.00% | 1833.00% | -4086.53% | -3.85 | 673.21% | 0.00% | 0.00% | 1303.49% | 0.66 | 0.78 | — | -12.03 |
| INM | InMed Pharmaceuticals Inc… | $0.85 | 1.54M | +1,918% | +653% | — | — | -0.25 | 0.11 | 0.42 | 1.66 | — | 0.13 | 34.53% | -160.20% | -165.14% | -52.84% | -173.20% | -43.65% | 0.06 | -21.22 | 6.99 | 6.27 | 1.94 | -5848.00% | 750.00% | 1103.00% | -377.16% | -3.10 | -169.90% | 0.00% | 0.00% | 311.23% | 1.52 | 1.55 | -2.43 | -10.26 |
| KZIA | Kazia Therapeutics Limite… | $8.45 | 13.69M | +90% | -63% | — | +12,468% | -0.63 | -1.56 | 309.03 | -0.68 | — | -1.38 | 100.00% | -33850.00% | -49290.48% | 226.03% | 112.59% | -149.76% | -0.05 | — | 0.35 | 0.32 | 0.30 | -6564.00% | -9818.00% | 3859.00% | -102.30% | -0.94 | 114.02% | 0.00% | 0.00% | 22.54% | -0.64 | -0.68 | 215.01 | -40.14 |
| SILO | Silo Pharma, Inc. | $0.37 | 2.92M | +5,090% | +86% | — | — | -1.09 | 0.95 | 66.36 | 0.52 | — | 1.00 | 91.90% | -6526.44% | -6092.59% | -78.37% | 266.27% | -57.96% | 0.00 | -925.59 | 4.29 | 4.28 | 0.89 | -83.00% | 0.00% | 1890.00% | -80.13% | -2.32 | 216.94% | 0.00% | 0.00% | 11.59% | 0.49 | 0.60 | -31.84 | -2.88 |
| SXTP | 60 Degrees Pharmaceutical… | $3.11 | 2.51M | +12,794% | +37,941,033% | — | — | -0.09 | 0.18 | 1.17 | 0.32 | 0.00 | 0.18 | 36.67% | -1598.97% | -1308.01% | -178.66% | -524.57% | -117.49% | 0.04 | -1227.87 | 3.25 | 2.34 | 0.19 | 185263.00% | 13961.00% | 2512.00% | -822.00% | -3.41 | -314.75% | 0.00% | 0.00% | 0.00% | 0.26 | 0.43 | -4.15 | -14.30 |
About Jaguar Health, Inc.
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.
- CEO
- Lisa A. Conte
- Employees
- 49
- Beta
- 0.12
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($5.77 ÷ $6.69) − 1 = -13.75% (DCF, example).